Apr 19 |
Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value
|
Apr 19 |
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
|
Apr 18 |
Ocugen stock jumps after $175M securities filing
|
Apr 12 |
Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets
|
Apr 10 |
Ocugen says EU backs a U.S. trial for gene therapy
|
Apr 10 |
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU400—Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication
|
Apr 8 |
Ocugen (OCGN) Up as DSMB Allows Cohort 2 Dosing in GA Study
|
Apr 8 |
Why Ocugen Shares Are Trading Higher
|
Apr 8 |
Ocugen stock gains after FDA nod to initiate Phase 3 trial of gene therapy candidate
|
Apr 8 |
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
|